[Skip to Navigation]
Sign In

Featured Clinical Reviews

August 19, 2022

New Reforms to Prescription Drug Pricing in the US: Opportunities and Challenges

Author Affiliations
  • 1Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
  • 2Division of Urological Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2022;328(11):1041-1042. doi:10.1001/jama.2022.15268

After several failed legislative efforts over the past decade, in August 2022, Congress enacted prescription drug pricing reforms as part of the Inflation Reduction Act.1 The law includes the most profound policy changes to prescription drug pricing since outpatient prescription drug coverage was introduced to Medicare (Part D) in 2003, including by allowing Medicare to directly negotiate prices for certain drugs, limiting price increases, and reducing out-of-pocket costs for Part D beneficiaries. The Congressional Budget Office initially estimated that these provisions would save the federal government $288 billion over 10 years.2

Add or change institution